最新发表
21.Zha, Z., S. R. Choi, L. Li, R. Zhao, K. Ploessl, X. Yao, D. Alexoff, L. Zhu, and H. F. Kung. "New PSMA-Targeting Ligands: Transformation from Diagnosis (Ga-68) to Radionuclide Therapy (Lu-177)." Journal of Medicinal Chemistry (2022) 65 (19), 13001-13012. DOI: 10.1021/acs.jmedchem.2c00852
20.Lee H, Scheuermann JS, Young AJ, Doot RK, Daube-Witherspoon ME, Schubert EK, Fillare MA, Alexoff D, Karp JS, Kung HF, Pryma DA. Preliminary Evaluation of 68Ga-P16-093, a PET Radiotracer Targeting Prostate-Specific Membrane Antigen in Prostate Cancer. Molecular Imaging and Biology. 2022 Mar 29:1-11.
19.Rui Guo, Xiangxi Meng, Fei Wang, Jiangyuan Yu, Qing Xie, Wei Zhao, Lin Zhu, Hank F. Kung, Zhi Yang and Nan Li ., 68Ga-P15-041, A Novel Bone Imaging Agent for Diagnosis of Bone Metastases.,Front. Oncol. 2021, 11:766851
18.Haiyan Hong, Guochang Wang, Karl Ploessl, Zhihao Zha, Jie Zang, Zhaohui Zhu, Lin Zhu, Hank F. Kung.,Kit-based preparation of [68Ga]Ga-P16-093 (PSMA-093) using different commercial 68Ge/68Ga generators, Nuclear Medicine and Biology 106 (2022):1-9
17.Zhang, Q., Zhao, X., Lei, P., Kung, H. F., Yang, Z., Zhu, L., Wang, S., Zhu, H., Meng, X., Duan, Y., Sun, L., Pan, J., Ma, R., Hong, H., Zhao, X., Demchuk, A., Smith, E. E., & Wang, Y. (2021). Evaluating [68Ga]Ga-p14-032 as a Novel PET Tracer for Diagnosis Cerebral Amyloid Angiopathy. Frontiers in neurology, 12, 702185. https://doi.org/10.3389/fneur.2021.702185
16.Wang G, Hong H, Zang J, Liu Q, Jiang Y, Fan X, Zhu Z, Zhu L, Kung HF. Head-to-head comparison of [68 Ga] Ga-P16-093 and [68 Ga] Ga-PSMA-617 in dynamic PET/CT evaluation of the same group of recurrent prostate cancer patients. European journal of nuclear medicine and molecular imaging. 2022 Feb;49(3):1052-62.
15.Li, L., Zhao, R., Hong, H., Li, G., Zhang, Y., Luo, Y., Zha, Z., Zhu, J., Qiao, J., Zhu, L. and Kung, H.F., 68Ga-labelled-exendin-4: New GLP1R targeting agents for imaging pancreatic β-cell and insulinoma. Nuclear medicine and biology, 2021.102, pp.87-96.
14. Xiao, Hao, Seok Rye Choi, Ruiyue Zhao, Karl Ploessl, David Alexoff, Lin Zhu, Zhihao Zha, and Hank F. Kung. "A new highly deuterated [18F] AV-45,[18F] D15FSP, for imaging β-amyloid plaques in the brain." ACS Medicinal Chemistry Letters (2021).12,1086-1092
13. Zha, Zhihao, Seok Rye Choi, Karl Ploessl, David Alexoff, Ruiyue Zhao, Lin Zhu, and Hank F. Kung. "Radiolabeling Optimization and Preclinical Evaluation of the New PSMA Imaging Agent [18F] AlF-P16-093." Bioconjugate Chemistry (2021),32(5), 1017-1026
12. Hong, H., Ploessl, K., Zha, Z., Wang, H., Guo, R., Xie, Q., Zhu, H., Yang, Z., Zhu, L. and Kung, H.F., 2021. "Development and validation of a kit formulation of [Ga-68] Ga-P15-041 as a bone imaging agent". Applied Radiation and Isotopes 169 (2021) 109485
11. Zha Z et al."Preclinical evaluation of [18F] D3FSP, deuterated AV-45, for imaging of β-amyloid in the brain." Nuclear Medicine and Biology 92 (2021)97-106.
10. Zhao, Ruiyue, Karl Ploessl, Zhihao Zha, Seokrye Choi, David Alexoff, Lin Zhu, and Hank F. Kung. "Synthesis and Evaluation of 68Ga-and 177Lu-Labeled (R)-vs (S)-DOTAGA Prostate-Specific Membrane Antigen-Targeting Derivatives." Molecular Pharmaceutics (2020) 17 (12), 4589-4602.
9. Green, Mark A., Gary D. Hutchins, Clinton D. Bahler, Mark Tann, Carla J. Mathias, Wendy Territo, Justin Sims et al. "[68 Ga] Ga-P16-093 as a PSMA-Targeted PET Radiopharmaceutical for Detection of Cancer: Initial Evaluation and Comparison with [68 Ga] Ga-PSMA-11 in Prostate Cancer Patients Presenting with Biochemical Recurrence." Molecular Imaging and Biology 22, no. 3 (2020): 752-763.
8. Gee, Antony D., Jan Andersson, Rajiv Bhalla, Yearn Seong Choe, David W. Dick, Matthias M. Herth, Eric D. Hostetler et al. "Training the next generation of radiopharmaceutical scientists." Nuclear Medicine and Biology 88 (2020): 10-13.
7. Yao X et al. "Synthesis and evaluation of novel radioiodinated PSMA targeting ligands for potential radiotherapy of prostate cancer." Bioorganic & Medicinal Chemistry 28, no. 5 (2020): 115319.
6. Shi S et al.. "[68Ga] Ga-HBED-CC-DiAsp: A new renal function imaging agent." Nuclear Medicine and Biology 82 (2020): 17-24.
5. Zha Z et al.. "A new [68Ga] Ga-HBED-CC-bisphosphonate as a bone imaging agent." Molecular Pharmaceutics 17 (5), 1674-1684(2020).
4. Doot R.K., et al. Biodistribution, dosimetry, and temporal signal-to-noise ratio analyses of normal and cancer uptake of [68Ga] Ga-P15-041, a gallium-68 labeled bisphosphonate, from first-in-human studies. Nuclear Medicine and Biology. 2020 (86-87):1-8
3. Xu X et al. "Dynamic PET/CT imaging of 18 F-(2 S, 4 R) 4-fluoroglutamine in healthy volunteers and oncological patients." European Journal of Nuclear Medicine and Molecular Imaging (2020): 1-13.
2. Zhang, L et al. “An Improved Preparation of [18F]AV-45 by Simplified Solid-Phase Extraction Purification.” Journal of labelled compounds & radiopharmaceuticals. 63.3 (2020): 108–118.
1. Liu S et al.. "Design, Synthesis and Evaluation of A Novel Glutamine Derivative (2S, 4R)-2-amino -4-cyano-4-[18F] fluoro-butanoic acid." New Journal of Chemistry 44:21 (2020): 9109-9117.
近期文章：
1. Zhang L et al.. "In vivo ester hydrolysis as a new approach in development of positron emission tomography tracers for imaging hypoxia." Molecular pharmaceutics 16, no. 3 (2019): 1156-1166.
2. Sun M et al. "Rapid screening of nine unradiolabeled candidate compounds as PET brain imaging agents using cassette-wave microdosing and LC-MS/MS." Journal of Chromatography B 1121 (2019): 28-38.
3. Yao X, Zha Z, Zhao R, Choi SR, Ploessl K, Liu F, Zhu L, Kung HF. Optimization of solid-phase extraction (SPE) in the preparation of [18F] D3FSP: A new PET imaging agent for mapping Aβ plaques. Nuclear Medicine and Biology. 2019 Apr 1;71:54-64.
4. Zhao R et al. "VMAT2 imaging agent, D6-[18F] FP-(+)-DTBZ: Improved radiosynthesis, purification by solid-phase extraction and characterization." Nuclear medicine and biology 72 (2019): 26-35.
5. Zhang Y et al. "Initial experience in synthesis of (2 S, 4 R)‐4‐[18F] fluoroglutamine for clinical application." Journal of Labelled Compounds and Radiopharmaceuticals 62, no. 5 (2019): 209-214.
6. Shi S et al.. "Synthesis of novel technetium-99m tricarbonyl-HBED-CC complexes and structural prediction in solution by density functional theory calculation." Royal Society Open Science 6, no. 11 (2019): 191247.
7. Xiao H et al. "Developing a cassette microdosing approach to enhance the throughput of PET imaging agent screening." Journal of pharmaceutical and biomedical analysis 154 (2018): 48-56.
8. Liu F et al. "Deuterium‐substituted 2‐(2′‐((dimethylamino) methyl)‐4′‐[18F](fluoropropoxy) phenylthio) benzenamine as a serotonin transporter imaging agent." Journal of Labelled Compounds and Radiopharmaceuticals 61, no. 8 (2018): 576-585.
9. Liu F et al. "Deuterated 18F-9-O-hexadeutero-3-fluoropropoxyl-(+)-dihydrotetrabenazine (D6-FP-(+)-DTBZ): A vesicular monoamine transporter 2 (VMAT2) imaging agent." Nuclear medicine and biology 57 (2018): 42-49.
10. Zhang Y et al. "Fluorine-18 labeled diphenyl sulfide derivatives for imaging serotonin transporter (SERT) in the brain." Nuclear medicine and biology 66 (2018): 1-9.
11. Zhu L et al.. "Metabolic imaging of glutamine in cancer." Journal of Nuclear Medicine 58, no. 4 (2017): 533-537.
12. Wu X et al.. "Brain uptake of a non-radioactive pseudo-carrier and its effect on the biodistribution of [18 F] AV-133 in mouse brain." Nuclear medicine and biology 42, no. 7 (2015): 630-636.
13. Zhu L et al.. "PET/SPECT imaging agents for neurodegenerative diseases." Chemical Society Reviews 43, no. 19 (2014): 6683-6691.
14. Zhu L et al.. "Expanding the scope of Fluorine tags for PET imaging." Science 342, no. 6157 (2013): 429-430.
15. Zhu L et al. "Imaging of VMAT2 binding sites in the brain by 18F-AV-133: The effect of a pseudo-carrier." Nuclear medicine and biology 39, no. 7 (2012): 897-904.
16. Zha Z et al. "Synthesis and evaluation of two novel 2-nitroimidazole derivatives as potential PET radioligands for tumor imaging." Nuclear medicine and biology 38, no. 4 (2011): 501-508.
17. Qu W et al. "Synthesis of optically pure 4-fluoro-glutamines as potential metabolic imaging agents for tumors." Journal of the American Chemical Society 133, no. 4 (2011): 1122-1133.
18. Liu Y et al. "Optimization of automated radiosynthesis of [18F] AV-45: a new PET imaging agent for Alzheimer's disease." Nuclear medicine and biology 37, no. 8 (2010): 917-925.
19. Zhu L et al."An improved radiosynthesis of [18F] AV-133: a PET imaging agent for vesicular monoamine transporter 2." Nuclear medicine and biology 37, no. 2 (2010): 133-141.
学术会议：
2022 Meeting
1.Bahler C, Green M, Tann M, Collins K, Swensson J, Brocken E, Cheng L, Mathias C, Alexoff D, Kung H, Hutchins G. PD27-01 PREDICTING EXTRA-PROSTATIC EXTENSION (EPE) FOR SURGICAL GUIDANCE IN PROSTATE CANCER: A COMPARISON OF BIOPSY PATHOLOGY, MULTIPARAMETRIC MRI, AND PSMA-PET. The Journal of Urology. 2022 May;207(Supplement 5):e493.
2021 Meeting
1. L Li, R Zhao, H Hong, Y Zhang, Z Zha, L Zhu, H Kung. [68Ga] Ga-HBED-CC-exendin-4: A new GLP1R targeting radiolabeled agent for pancreas β-cell and insulinoma imaging.Nuclear Medicine and Biology 96, (2021) S47-S48
2.Wang, Guochang, Jie Zang, Haiyan Hong, Qingxing Liu, Yuanyuan Jiang, Zhaohui Zhu, Lin Zhu, and Hank Kung. "A pilot prospective comparison of [68Ga] Ga-P16-093 and [68Ga] Ga-PSMA-617 in the same group of prostate cancer patients." Journal of Nuclear Medicine 62 (supplement 1), (2021): 1329-1329.
3. Zhang, Qihui, Xiaobin Zhao, Hank F. Kung, Zhi Yang, Lin Zhu, Peng Lei, Shujing Wang et al. "Abstract P339: Evaluating Ga68 Regional Distribution as a New Pet Tracerfor Diagnosis Cerebral Amyloid Angiopathy." Stroke 52, no. Suppl_1 (2021): AP339-AP339.
2020 SNMMI Meeting
（https://am.snmmi.org/imis/SNMMI-AM/Home/SNMMI-AM/Home.aspx）
1. PSMA-targeted PET with [68Ga] Ga-P16-093: Assessment of potential role in surgical planning for patients with intermediate-risk and high-risk prostate cancer. C Bahler, M Tann, M Green, G Hutchins, C Mathias, R Whaley, L Cheng, ... Journal of Nuclear Medicine 61 (supplement 1), 1252-1252
2. PSMA-targeted PET with [68Ga] Ga-P16-093: Initial evaluation in intermediate-risk and high-risk prostate cancer patients prior to prostatectomy M Green, C Bahler, M Tann, G Hutchins, C Mathias, W Territo, R Whaley, ... Journal of Nuclear Medicine 61 (supplement 1), 192-192
2019 ISRS Meeting（Beijing）
1. Kung, Hank F. "Development of radiopharmaceutical; from bench to FDA approved clinical application." In JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, vol. 62, pp. S80-S80., 2019.
2. Zhang L et al. "An improved method for preparing [F-18] AV-45 using solid-phase extraction purification." In JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, vol. 62, pp. S173-S174. 2019.
3. Zhang Y et al. "Automated radiosynthesis of (2S, 4R)-4-[F-18] fluoroglutamine for clinical application." In JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, vol. 62, pp. S322-S323. 2019.
4. Huang Y et al. "Synthesis and radiolabeling of a novel glutamine derivative:(2S, 4S) 4-[F-18] FEBGln." In JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, vol. 62, pp. S436-S438. 2019.
5. Hong H, et al. "A simple kit-based preparation of [Ga-68] Ga-P15-041: A novel bone imaging agent." JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS. Vol. 62. 2019.
6. Kung H et al. "[Ga-68]/[Lu-177] P17-087: A potential theranostic agent targeting PSMA expressing tumor." In JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, vol. 62, pp. S99-S100. 2019.
7. Shi S et al.. "[Ga-68] Ga-HBED-CC-DiAsp: A new renal function imaging agent." In JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, vol. 62, pp. S269-S271. 2019.
2019 SNMMI Meeting
1. Green, M., Hutchins, G., Fletcher, J., Bahler, C., Tann, M., Sims, J., Mathias, C., Territo, W., Polson, H., Alexoff, D. and Kung, H., 2019. Initial evaluation of the PSMA-targeted PET agent [68Ga] Ga-P16-093, and comparison with [68Ga] Ga-PSMA-11, in prostate cancer patients presenting with biochemical recurrence. Journal of Nuclear Medicine, 60(supplement 1), pp.9-9.
2. Zhao, Ruiyue, Zhihao Zha, Karl Ploessl, Seok Choi, Futao Liu, Lin Zhu, and Hank Kung. "Improved preparation of D6-[18F] FP-(+)-DTBZ: A new vesicular monoamine transporter 2 (VMAT2) imaging agent." Journal of Nuclear Medicine 60, no. supplement 1 (2019): 1617-1617.
3. Yao, Xinyue, Ruiyue Zhao, Zhihao Zha, Seok Choi, Karl Ploessl, David Alexoff, Lin Zhu, and Hank Kung. "Optimization of solid phase extraction (SPE) in preparation of D3-[18F] FSP: A new PET imaging agent for mapping Aβ plaques." Journal of Nuclear Medicine 60, no. supplement 1 (2019): 485-485.
4. Wong, Dean, Hiroto Kuwabara, Kelly Kitzmiller, Ayon Nandi, Zabecca Brinson, Noble George, David Alexoff et al. "Comparison of [18F] D3FSP ([18F] P16-129) and [18F] AV45 in Alzheimer’s Disease." Journal of Nuclear Medicine 60, no. supplement 1 (2019): 1457-1457.